Avalo Therapeutics (AVTX) Other Operating Expenses (2017 - 2024)

Avalo Therapeutics (AVTX) has 7 years of Other Operating Expenses data on file, last reported at $87000.0 in Q4 2024.

• Quarterly Other Operating Expenses fell 97.64% year-over-year to $87000.0 in Q4 2024, while the trailing twelve-month figure through Sep 2025 was $87000.0 (down 99.72% YoY) and the FY2024 annual result came in at $27.3 million, up 425.43% from the prior year.
• Other Operating Expenses advanced to $87000.0 in Q4 2024, from -$714000.0 in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $27.5 million in Q1 2024 to a low of -$714000.0 in Q3 2024.
• A 4-year average of $4.0 million and a median of $655500.0 in 2021 frame the typical range for Other Operating Expenses.
• The widest YoY moves for Other Operating Expenses: up 4883.3% in 2024, down 389.07% in 2024.
• Tracing AVTX's Other Operating Expenses over 4 years: stood at $691000.0 in 2021, then declined by 10.27% to $620000.0 in 2022, then jumped by 494.52% to $3.7 million in 2023, then plunged by 97.64% to $87000.0 in 2024.
• The last three Other Operating Expenses figures came in at $87000.0 (Q4 2024), -$714000.0 (Q3 2024), and $446000.0 (Q2 2024), per Business Quant data.